N6-(4-Hydroxybenzyl)adenosine - CAS 110505-75-4
Catalog number: 110505-75-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
P2Y Receptor
N6-(4-Hydroxybenzyl)adenosine, an imidazopyrimidine derivative, could be effective as an inhibitor of platelet aggregation. IC50: 6.77-141 μM.
N6-(4-Hydroxybenzyl)-adenosine; 110505-75-4; N6-(4-hydroxybenzyl)adenine riboside; N6-(4-hydroxybenzyl)adenosine; CHEMBL224024; P-Topolin riboside
DMSO:≥ 3.8 mg/mL
-20ºC Freeze
N6-(4-Hydroxybenzyl)adenosine, an imidazopyrimidine derivative, could be effective as an inhibitor of platelet aggregation.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Canonical SMILES:
1.Design and synthesis of novel dual-action compounds targeting the adenosine A(2A) receptor and adenosine transporter for neuroprotection.
Chen JB;Liu EM;Chern TR;Yang CW;Lin CI;Huang NK;Lin YL;Chern Y;Lin JH;Fang JM ChemMedChem. 2011 Aug 1;6(8):1390-400. doi: 10.1002/cmdc.201100126. Epub 2011 Jun 20.
A novel compound, N⁶-(4-hydroxybenzyl)adenosine, isolated from Gastrodia elata and which has been shown to be a potential therapeutic agent for preventing and treating neurodegenerative disease, was found to target both the adenosine A(2A) receptor (A(2A) R) and the equilibrative nucleoside transporter 1 (ENT1). As A(2A) R and ENT1 are proximal in the synaptic crevice of striatum, where the mutant huntingtin aggregate is located, the dual-action compounds that concomitantly target these two membrane proteins may be beneficial for the therapy of Huntington's disease. To design the desired dual-action compounds, pharmacophore models of the A(2A) R agonists and the ENT1 inhibitors were constructed. Accordingly, potentially active compounds were designed and synthesized by chemical modification of adenosine, particularly at the N⁶ and C⁵' positions, if the predicted activity was within an acceptable range. Indeed, some of the designed compounds exhibit significant dual-action properties toward both A(2A) R and ENT1. Both pharmacophore models exhibit good statistical correlation between predicted and measured activities. In agreement with competitive ligand binding assay results, these compounds also prevent apoptosis in serum-deprived PC12 cells, rendering a crucial function in neuroprotection and potential utility in the treatment of neurodegenerative diseases.
2.[Determination of N6-(4-hydroxybenzyl) adenine riboside in rat plasma by ultra performance liquid chromatography-quadrupole time of flight mass spectrometry].
Tang C;Wang L;Cheng M;Liu X;Xiao H Se Pu. 2015 Jul;33(7):699-703.
An ultra performance liquid chromatography-quadrupole time of flight mass spectrometry (UPLC-QTOF-MS) method was developed and validated for the determination of N6-(4-hydroxybenzyl) adenine riboside and its pharmacokinetics in rat plasma. The chromatographic conditions were optimized. The separation was performed on an Agilent ZORBAX SB-C18 column(150 mm x 3 mm, 1.8 μm) with a gradient elution of 0.2% (v/v) formic acid aqueous solution and acetonitrile as the mobile phases at a flow rate of 0.35 mL/min. The detection was accomplished in positive mode with electrospray ionization (ESI) by UPLC-QTOF-MS, and 6-benzylamino purine was used as the internal standard (IS). The results showed that the linear range of calibration curve was 0.625-160 ng/mL for N6-(4-hydroxybenzyl) adenine riboside in rat plasma with the correlation coefficient more than 0.99. The recoveries were 88.41%-108.26%. The limit of detection was 0.1 ng/mL. The intra-day and inter-day precisions (RSDs) were less than 6%, and intra-day and inter-day accuracies (REs, RE = (measured concentration-spiked concentration)/spiked concentration x 100%) were less than ±15%. The method is rapid, sensitive and accurate for the quantitation of N6-(4-hydroxybenzyl) adenine riboside, which can be used for the study of pharmacokinetics of N6-(4-hydroxybenzyl) adenine riboside.
3.Neuroprotective principles from Gastrodia elata.
Huang NK;Chern Y;Fang JM;Lin CI;Chen WP;Lin YL J Nat Prod. 2007 Apr;70(4):571-4. Epub 2007 Mar 24.
Serum deprivation-induced neuronal-like PC12 cell apoptosis was used as an ischemic/hypoxic model to screen neuroprotective compounds from the rhizomes of Gastrodia elata, a traditional Chinese medicine. Two active compounds, bis(4-hydroxybenzyl)sulfide (1) and N6-(4-hydroxybenzyl)adenine riboside (2), together with 15 known compounds were obtained from the active fraction. Compound 2 was further elucidated by chemical synthesis. Compounds 1 and 2 potently prevented PC12 cell apoptosis in concentration-dependent manners with EC50 values of 7.20 microM and 3.7 x 10-8 M, respectively, and IC50 values of 42.90 microM (Ki 24.10 microM) and 4.660 microM (Ki 2.620 microM), respectively, in an adenosine A2A receptor binding assay.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related P2Y Receptor Products

CAS 1228271-30-4 MRS 2957 triethylammonium salt

MRS 2957 triethylammonium salt
(CAS: 1228271-30-4)

MRS 2957 triethylammonium salt 7 is a selective P2Y6 receptor agonists (EC50 = 12 nM) for the treatment of muscle wasting and neurodegeneration. It exhibits 14-...

CAS 120202-66-6 Clopidogrel

(CAS: 120202-66-6)

Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes.

CAS 145-63-1 Suramin

(CAS: 145-63-1)

Suramin, also called as Germanin, has been demonstrated to inhibit a large variety of enzymes including urease, hexokinase, succinic dehydrogenase, p-glucuronid...

CAS 711019-86-2 MRS 2578

MRS 2578
(CAS: 711019-86-2)

MRS2578 is a potent P2Y6 receptor antagonist with IC50 of 37 nM, exhibits insignificant activity at P2Y1, P2Y2, P2Y4,and P2Y11 receptors.

CAS 274693-27-5 Ticagrelor

(CAS: 274693-27-5)

Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in...

CAS 150322-43-3 Prasugrel

(CAS: 150322-43-3)

Prasugrel is a thienopyridine prodrug that is converted by esterases to a receptor antagonist for purinergic P2Y12 receptors. The blockade of P2Y12 receptor act...

CAS 436847-09-5 MRS 2365

MRS 2365
(CAS: 436847-09-5)

MRS 2365 is a highly potent, selective P2Y1 receptor agonist (EC50 = 0.4 nM), with no activity at P2Y12 receptors and only very low agonist activity at P2Y13 re...

CAS 211427-08-6 Diquafosol tetrasodium

Diquafosol tetrasodium
(CAS: 211427-08-6)

Diquafosol tetrasodium, also referred to Diquas, is aP2Y2receptor agonist that is targeted to treat dry eye disease through rehydration of the ocular surface.

Quick Inquiry

Verification code

Featured Items